Background
Esophageal cancer, cancer death, ESCC
ESOPHAGEAL CANCER
Esophageal cancer ranks as the sixth most common cause of cancer death globally [The CROSS study and NEOCRTEC5010 study confirmed that neoadjuvant chemoradiotherapy (nCRT) can significantly improve the long-term survival of ESCC patients after surgery [In recent years, neoadjuvant immunotherapy combined with chemotherapy (nICT) has been the most promising research frontier for multidisciplinary treatment of locally advanced ESCC [Hence, we designed this prospective single-arm, phase II trial (PILOT trial) to assess the safety and efficacy of perioperative immunotherapy in locally advanced resectable ESCC and answer the questions that CheckMate 577 did not cover.